Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1].
Molecular Weight:
(144.08 kDa)
Purity:
97.45
CAS Number:
[1463459-96-2]
Target:
Anaplastic lymphoma kinase (ALK)
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted